The Ferring F.I.V.E. Initiative

Latest News

Saint-Prex, Switzerland, 13 July 2015 – Ferring Pharmaceuticals announced today that it will collaborate with Baltimore-based Intralytix, Inc. in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).

Manufacturing

For medical information or customer service related inquiries or to report an adverse event or product complaint, please call
1-888-FERRING
(1-888-337-7464)

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

EUFLEXXA, FIRMAGON, and PREPOPIK are registered trademarks of Ferring B.V. ZOMACTON is a trademark of Ferring B.V.